Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Atripla to Eviplera and neurocognitive functioning in suppressed HIV infection
NL-OMON40774Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tenofovir disoproxil fumarate and emtricitabine + rilpivirine + tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Neurocognitive performance. Planned start Jan 2015; status: withdrawn.
02
Drugs
tenofovir disoproxil fumarateemtricitabine + rilpivirine + tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON40774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40774.